Economic Observation Network DeKang Medical (DXCM) has recently received rating upgrades from multiple institutions and is promoting the new generation G7 sensors, which has attracted market attention for related track dynamics.

Institutional Perspective
Emperor Capital Market raised its target price from $85 to $105 in early October, maintaining a buy (market consensus, non return commitment) On October 8th, Citigroup once again listed DeKang as the top choice stock in the medical technology sector, citing clear revenue growth, improved profit margins, and expanded market share 。

Business Progress
The company is promoting the promotion of the new generation G7 15 Day sensor and expanding the product coverage for patients with type 2 diabetes This type of commercialization progress is usually reflected in share data earlier than in financial reports.

Industry Status
Abbott's Q3 financial report (October) and CGM business growth rate in the same track will directly affect the market's emotional evaluation of the entire CGM track 。

The above content is based on publicly available information and does not constitute investment advice.